Acceleron Pharma Inc (XLRN) Given Average Recommendation of “Buy” by Brokerages

Acceleron Pharma Inc (NASDAQ:XLRN) has been given an average rating of “Buy” by the twenty analysts that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $46.33.

Several equities research analysts have recently issued reports on XLRN shares. Credit Suisse Group set a $51.00 price target on shares of Acceleron Pharma and gave the stock a “buy” rating in a research note on Tuesday, November 14th. HC Wainwright started coverage on shares of Acceleron Pharma in a research note on Thursday, October 12th. They set a “buy” rating and a $57.00 price target for the company. Royal Bank of Canada restated a “hold” rating on shares of Acceleron Pharma in a research note on Thursday, November 2nd. Oppenheimer restated a “hold” rating on shares of Acceleron Pharma in a research note on Tuesday, November 14th. Finally, ValuEngine lowered shares of Acceleron Pharma from a “hold” rating to a “sell” rating in a research note on Friday, October 6th.

Acceleron Pharma (NASDAQ XLRN) traded up $0.69 during trading on Friday, hitting $43.04. 197,438 shares of the company’s stock traded hands, compared to its average volume of 275,733. Acceleron Pharma has a 1 year low of $23.07 and a 1 year high of $46.93. The company has a market cap of $1,915.70, a PE ratio of -16.62 and a beta of 1.59.

Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.67) by $0.02. Acceleron Pharma had a negative net margin of 759.34% and a negative return on equity of 40.70%. The company had revenue of $3.00 million during the quarter, compared to analyst estimates of $3.52 million. During the same quarter last year, the business posted ($0.55) EPS. Acceleron Pharma’s quarterly revenue was up .0% compared to the same quarter last year. research analysts anticipate that Acceleron Pharma will post -2.65 earnings per share for the current fiscal year.

In related news, EVP Matthew L. Sherman sold 4,633 shares of Acceleron Pharma stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $42.71, for a total value of $197,875.43. Following the completion of the transaction, the executive vice president now directly owns 77,700 shares in the company, valued at approximately $3,318,567. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Christopher Rovaldi sold 2,266 shares of Acceleron Pharma stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $42.42, for a total transaction of $96,123.72. Following the completion of the transaction, the senior vice president now owns 52,977 shares of the company’s stock, valued at $2,247,284.34. The disclosure for this sale can be found here. Insiders sold a total of 146,021 shares of company stock valued at $5,529,598 over the last quarter. 3.90% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP grew its position in shares of Acceleron Pharma by 416.3% during the 3rd quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 2,352 shares in the last quarter. BNP Paribas Arbitrage SA grew its position in shares of Acceleron Pharma by 969.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 3,288 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new position in shares of Acceleron Pharma during the 3rd quarter valued at $225,000. Trexquant Investment LP purchased a new position in shares of Acceleron Pharma during the 3rd quarter valued at $266,000. Finally, PNC Financial Services Group Inc. grew its position in shares of Acceleron Pharma by 57.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 8,460 shares of the biopharmaceutical company’s stock valued at $258,000 after purchasing an additional 3,100 shares in the last quarter. Hedge funds and other institutional investors own 85.70% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/20/acceleron-pharma-inc-xlrn-given-average-recommendation-of-buy-by-brokerages.html.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Analyst Recommendations for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply